Varsha Bhat

Varsha Bhat

Auto-generated profile, based on publicly available information

Varsha Bhat

Center for Integrative Genomics School of Biological Sciences, Georgia Institute of Technology Atlanta Georgia USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Alternatives to Laboratory Animals
Verified
Journal Article
Open access
PDF file
VBVarsha Bhat
Varsha Bhat
JCJhinuk Chatterjee
Jhinuk Chatterjee
The current strategy for treating the Covid-19 coronavirus disease involves the repurposing of existing drugs or the use of convalescent plasma therapy, as no specific therapeutic intervention has yet received regulatory approval. However, severe adverse effects have been reported for some of these repurposed drugs. Recently, several in silico studies have identified compounds that are potential inhibitors of the main protease (3-chymotrypsin-like cysteine protease) and the nucleocapsid protein of SARS-CoV-2. An essential step of drug development is the careful evaluation of toxicity, which has a range of associated financial, temporal and ethical limitations. In this study, a number of in silico tools were used to predict the toxicity of 19 experimental compounds. A range of web-based servers and applications were used to predict hepatotoxicity, mutagenicity, acute oral toxicity, carcinogenicity, cardiotoxicity, and other potential adverse effects. The compounds were assessed based on the consensus of results, and were labelled as positive or negative for a particular toxicity endpoint. The compounds were then categorised into three classes, according to their predicted toxicity. Ten compounds (52.6%) were predicted to be non-mutagenic and non-hERG inhibitors, and exhibited zero or low level hepatotoxicity and carcinogenicity. Furthermore, from the consensus of results, all 19 compounds were predicted to be non-mutagenic and negative for acute oral toxicity. Overall, most of the compounds displayed encouraging toxicity profiles. These results can assist further lead optimisation studies and drug development efforts to combat Covid-19.

17 November 2024 in British Journal of Haematology
Verified
Journal Article
Closed access
VBVarsha Bhat
Varsha Bhat
APAlka A. Potdar
Alka A. Potdar
GYG. Karen Yu
G. Karen Yu
GGGreg Gibson
Greg Gibson
Vivien SheehanVivien Sheehan
Vivien Sheehan

9 February 2022 in Research Square
Verified
Preprint
Open access
PDF file
VBVarsha Bhat
Varsha Bhat
ASAditi Lakshmi S
Aditi Lakshmi S
AMAbhinaya Muraly
Abhinaya Muraly
PRPranathi Rao
Pranathi Rao
JCJhinuk Chatterjee
Jhinuk Chatterjee
SARS-CoV-2 is known to primarily cause mild to severe respiratory infections as well as chemosensory disturbances such as anosmia. Furthermore, it has been associated with the occurrence of neurological symptoms. In this study probable route of neuroinvasion by SARS-CoV-2 from the olfactory epithelium to the central nervous system was suggested and an agent-based model has been developed using NetLogo 3D. A series of simulations were performed to analyze real-world infection patterns; based on these simulations, it was observed that there is a direct correlation between the age of the patient and the day of neuroinvasion onset.